vps34-in-1

Vps34-IN-1 (VPS34-IN1) is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM in vitro, which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

HIV-1 Rev (34-50) (HIV-1 rev Protein (34-50)) is a 17 amino acid peptide with anti-HIV-1 activity. HIV-1 Rev (34-50) is derived from the Rev-responsive element-binding domains of Rev in HIV-1.

Human PTHrP-(1-34)NH2, also known as PTH-Related Protein (1-34) amide for human, mouse, and rat, is the N-terminal fragment of PTHrP. This peptide induces hypercalcemia and is utilized in the study of humoral hypercalcemia of malignancy [1].

GLP-2 (1-34) (human), a polypeptide secreted from the intestine shortly after eating, is utilized in research related to bone remodeling processes [1].

Parathyroid hormone (PTH) receptor agonist. Increases serum PTH levels and bone mass in rats.

Parathyroid Hormone (1-34), bovine TFA, a potent agonist of the parathyroid hormone (PTH) receptor, elevates calcium and inorganic phosphate levels in vivo. This compound is employed in osteoporosis research [1].

This is a fragment of beta-amyloid peptide. It has amino acids 1 through 34.

Parathyroid Hormone (1-34), bovine is a parathyroid hormone (PTH) receptor agonist that is part of the parathyroid hormone family. Parathyroid Hormone (1-34), bovine is used to study osteoporosis and hypoparathyroidism.

HIV-1 inhibitor-34 (compound 5q) is a potent, selective HIV-1 inhibitor that acts on HIV-1 (EC50: 6.4 nM), MT-4 cells (CC50: 16 μM). HIV-1 inhibitor-34 can be used in AIDS research.

Parathyroid Hormone (1-34), human, biotinylated serves as a probe targeting the parathyroid hormone receptor. It is utilized in the analysis of interactions between parathyroid hormone and its receptors within living cells and facilitates the purification of hormone-receptor complexes using affinity columns [1] [2].

Parathyroid hormone (1-34) (rat) (acetate) is a parathyroid hormone variant that enhances the structure of both cortical and cancellous bones. It is utilized in osteoporosis research [1] [2].

PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (K D = 0.1554 μM), resulting in the activation of the immune microenvironment and suppression of tumor growth [1].

Beclin1-ATG14L Interaction Inhibitor 1 (COM 19) is a selective inhibitor targeting the specific interaction between Beclin1 and ATG14L. It impedes the formation of complex I in the lipid kinase VPS34, thus inhibiting autophagy, while leaving complex II intact, which relies on the Beclin 1-UVRAG interaction for its integrity and is essential for vesicle transport [1].